Search research articles
Contact Us
Filters
Showing results (1-10 of 143) with videos related to
Page
of 15
Sort By:
Expert Opinion on Drug Metabolism & Toxicology
|
September 15, 2020
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
Jean-Michel Azorin, Nicolas Simon
Neuropsychiatric Disease and Treatment
|
April 15, 2014
Effectiveness of methylphenidate as augmentation therapy after failure of adjunctive neuromodulation for patients with treatment-refractory bipolar depression: a case report
Marc Adida, Jean-Michel Azorin
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
May 15, 2014
Clinical decision making in the treatment of mixed states
Heinz Grunze, Jean Michel Azorin
American Journal of Medical Genetics
|
November 29, 2002
Schizophrenia: two-faced meaning of vulnerability
Jean-Michel Azorin, Jean Naudin
Drugs
|
August 31, 2019
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder
Jean-Michel Azorin, Nicolas Simon
Expert Opinion on Pharmacotherapy
|
February 25, 2009
An update on the treatment of bipolar depression
Jean-Michel Azorin, Arthur Kaladjian
Expert Opinion on Pharmacotherapy
|
July 19, 2012
Clozapine for the treatment of schizophrenia
Eric Fakra, Jean-Michel Azorin
CNS Drugs
|
November 21, 2007
Valproate use in children and adolescents with bipolar disorder
Jean Michel Azorin, Robert L Findling
Medicina (Kaunas, Lithuania)
|
August 27, 2021
The Impact of Bipolar Disorder on Couple Functioning: Implications for Care and Treatment. A Systematic Review
Jean-Michel Azorin, Antoine Lefrere, Raoul Belzeaux
Expert Opinion on Drug Metabolism & Toxicology
|
August 18, 2022
Comorbidities and the right dose: antipsychotics
Nicolas Simon, Romain Torrents, Jean-Michel Azorin
Page
of 15
Search research articles
Search
Showing results (1-10 of 143) with videos related to
Sort By:
Page
of 15
Expert Opinion on Drug Metabolism & Toxicology
|
September 15, 2020
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
Jean-Michel Azorin, Nicolas Simon
Neuropsychiatric Disease and Treatment
|
April 15, 2014
Effectiveness of methylphenidate as augmentation therapy after failure of adjunctive neuromodulation for patients with treatment-refractory bipolar depression: a case report
Marc Adida, Jean-Michel Azorin
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
May 15, 2014
Clinical decision making in the treatment of mixed states
Heinz Grunze, Jean Michel Azorin
American Journal of Medical Genetics
|
November 29, 2002
Schizophrenia: two-faced meaning of vulnerability
Jean-Michel Azorin, Jean Naudin
Drugs
|
August 31, 2019
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder
Jean-Michel Azorin, Nicolas Simon
Expert Opinion on Pharmacotherapy
|
February 25, 2009
An update on the treatment of bipolar depression
Jean-Michel Azorin, Arthur Kaladjian
Expert Opinion on Pharmacotherapy
|
July 19, 2012
Clozapine for the treatment of schizophrenia
Eric Fakra, Jean-Michel Azorin
CNS Drugs
|
November 21, 2007
Valproate use in children and adolescents with bipolar disorder
Jean Michel Azorin, Robert L Findling
Medicina (Kaunas, Lithuania)
|
August 27, 2021
The Impact of Bipolar Disorder on Couple Functioning: Implications for Care and Treatment. A Systematic Review
Jean-Michel Azorin, Antoine Lefrere, Raoul Belzeaux
Expert Opinion on Drug Metabolism & Toxicology
|
August 18, 2022
Comorbidities and the right dose: antipsychotics
Nicolas Simon, Romain Torrents, Jean-Michel Azorin
Page
of 15